|
Mr. Daniel Spiegelman has served as Senior Vice President and Chief Financial Officer of CV Therapeutics since September 1999. He also served as Vice President and Chief Financial Officer from January 1998 to September 1999. From 1991 until 1998, he was employed by Genentech, Inc., holding various positions in the treasury department, including the position of Treasurer from 1996 to 1998. Mr. Spiegelman is a member of the board of directors of Cyclacel Pharmaceuticals and Affymax Inc.
Mr. Spiegelman holds a BA in economics from Stanford University and an MBA from the Stanford Graduate School of Business.
| 